For decades, the symptoms of perimenopause and menopause were waved away as the ordinary price of getting older — something to be endured quietly. The biology says otherwise. These are the downstream effects of a profound hormonal shift, they are measurable, and most of them respond to treatment.
Each section below opens with what the symptom is and what the data show, then offers a "How it works" panel you can expand if you want the physiology in more depth. Every figure is cited.
Vasomotor symptoms — hot flashes & night sweats
Sudden waves of heat, flushing, and sweating, often worst at night.
Long dismissed as a brief nuisance, vasomotor symptoms are neither brief nor minor. In the SWAN cohort, frequent hot flashes lasted a median of 7.4 years and persisted a median of 4.5 years after the final period — far longer than the "few years" of older guidance.1
How it works
Falling and fluctuating estrogen destabilizes the brain's thermoregulatory center in the hypothalamus, narrowing the "thermoneutral zone" — the range of core temperature the body tolerates without acting. Once that zone is narrow, a tiny rise in temperature triggers an outsized heat-dumping response: blood vessels dilate, you flush, you sweat, and a rebound chill often follows.
This matters beyond comfort: frequent, severe hot flashes are associated with early markers of cardiovascular disease, a link explored in the cardiovascular section below.8
Genitourinary syndrome of menopause (GSM)
Vaginal dryness, pain with sex, urinary urgency and frequency, recurrent UTIs.
Unlike hot flashes, GSM tends to worsen over time rather than fade. The 2014 decision by two professional societies to rename "vulvovaginal atrophy" as genitourinary syndrome of menopause was itself a correction — the old term ignored the urinary symptoms and carried needless stigma.2 It is also one of the most treatable of all menopausal complaints.
How it works
Estrogen receptors are densely expressed in the vulva, vagina, urethra, and bladder. As estrogen falls, these tissues thin and lose elasticity, blood flow drops, lubrication declines, and the vaginal pH rises as protective lactobacilli die back — raising susceptibility to irritation and infection.
Because the changes are structural and ongoing, they typically persist or progress without treatment — which is why local therapy is so effective at reversing them.
Sexual health & desire
Reduced libido, changes in arousal, orgasm, and genital sensitivity.
Sexual difficulties in midlife are usually multifactorial: declining testosterone and estrogen act on desire and sensitivity, while GSM can make sex physically painful, creating a cycle of avoidance. The androgen contribution is real and treatable — a 52-week randomized trial found that a testosterone patch produced a modest but clinically meaningful improvement in desire and satisfying sexual activity in postmenopausal women,3 a finding since confirmed by a systematic review and meta-analysis of randomized data.4
How it works
Women produce testosterone in the ovaries and adrenal glands, and levels fall gradually with age — by midlife, well below their peak. Testosterone contributes to desire (via the central nervous system) and to genital sensitivity and blood flow locally. Estrogen loss, meanwhile, drives the tissue changes of GSM.
Despite the trial evidence, there is currently no testosterone product approved specifically for women in the United States — a regulatory gap, not an evidence gap, discussed in Treatment Options.
Cognitive changes — "brain fog"
Word-finding lapses, forgetfulness, slower mental processing.
The fog is real, and reassuringly, it usually lifts. In the SWAN study, women's ability to improve with practice on a processing-speed task stalled during perimenopause — matching the lapses they reported — but then recovered in early postmenopause.5 In other words, this is typically a time-limited dip tied to the transition, not the onset of dementia.
How it works
Estrogen supports circuits involved in memory and processing speed, and the wide hormonal swings of perimenopause may be harder on the brain than the stable low levels that follow. SWAN found that mood, anxiety, and sleep disruption each shaved a little off cognitive performance — but they did not fully account for the perimenopausal dip, suggesting the hormonal transition itself plays a direct role.5
Mood & sleep
New or worsened depression, anxiety, irritability, and insomnia.
The menopausal transition carries a markedly elevated risk of depression: the Harvard Study of Moods and Cycles found women entering perimenopause were roughly twice as likely to develop significant depressive symptoms, even with no prior history.6 And it is treatable on the hormonal axis — a randomized trial showed transdermal estradiol plus intermittent micronized progesterone prevented depressive symptoms in perimenopausal and early postmenopausal women.7
How it works
Estrogen acts as a neuromodulator, influencing serotonin and other systems that regulate mood. Night sweats fragment sleep, and poor sleep worsens mood and cognition — a bidirectional loop. Because perimenopausal depression can appear in women with no psychiatric history and may respond to estrogen, treating it as ordinary depression without considering the hormonal driver can miss the cause.7
Metabolic changes
Weight shifting to the abdomen, reduced insulin sensitivity, less favorable lipids.
Many women notice that their body changes at midlife in ways that diet and exercise alone don't fully explain. The transition is associated with a shift of fat toward the abdomen (visceral fat) and less favorable metabolic and lipid profiles — changes that go beyond what aging alone would predict, and that hormone therapy can partly offset.910
How it works
Before menopause, estrogen favors insulin sensitivity and steers fat toward the hips and thighs. As it declines, fat redistributes to the metabolically riskier visceral depot, insulin resistance tends to rise, and lipid profiles shift unfavorably. "Eat less, move more" still matters — but the hormonal change alters where fat is stored and how efficiently it is burned, which is why the same habits can produce different results than they once did.
Bone
Accelerated bone loss around the final period; rising fracture risk.
Bone loss speeds up sharply in the years bracketing the final menstrual period, raising the long-term risk of osteoporosis and fracture. This is also where hormone therapy's benefit is least controversial: it prevents bone loss and reduces fracture risk.9
How it works
Estrogen restrains osteoclasts — the cells that break bone down. When estrogen falls, resorption outpaces formation and the skeleton loses density fastest in the trabecular bone of the spine and wrist. Because the steepest losses cluster around the final period, the years immediately before and after menopause are a critical window for protecting bone.
Cardiovascular
Cardiovascular risk rises after menopause — and hot flashes may be a signal.
Heart disease is the leading cause of death in women, and risk accelerates after menopause as estrogen's protective effects on blood vessels are lost. Notably, severe vasomotor symptoms appear to be more than a nuisance: in SWAN, women with early-onset or persistent hot flashes had greater carotid-artery wall thickness — an early marker of atherosclerosis.8
How it works
Estrogen helps keep blood vessels flexible and supports a favorable lipid profile; its loss is associated with arterial stiffening and adverse lipid changes. Crucially, timing shapes how hormone therapy interacts with this process — benefit is tied to starting near menopause rather than years later, the central thread of The HRT Story.10
These rarely arrive one at a time.
Night sweats fragment sleep, which feeds low mood and brain fog; GSM makes intimacy painful, which compounds sexual difficulty. The symptoms cluster — which is part of why they're so disruptive, and part of why addressing the underlying hormonal shift can help on several fronts at once.
The encouraging part: the evidence for treatment is strongest precisely for the most disruptive symptoms. The next step is what the options actually are — and how well each one works.
References
Every figure above links to its source. These references also appear in the site-wide bibliography.
- Avis NE, Crawford SL, Greendale G, et al; Study of Women's Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med. 2015;175(4):531–539. doi:10.1001/jamainternmed.2014.8063
- Portman DJ, Gass MLS; Vulvovaginal Atrophy Terminology Consensus Conference Panel. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy. Menopause. 2014;21(10):1063–1068.
- Davis SR, Moreau M, Kroll R, et al; APHRODITE Study Team. Testosterone for low libido in postmenopausal women not taking estrogen. N Engl J Med. 2008;359(19):2005–2017. doi:10.1056/NEJMoa0707302
- Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754–766. doi:10.1016/S2213-8587(19)30189-5
- Greendale GA, Huang MH, Wight RG, et al. Effects of the menopause transition and hormone use on cognitive performance in midlife women. Neurology. 2009;72(21):1850–1857. doi:10.1212/WNL.0b013e3181a71193
- Cohen LS, Soares CN, Vitonis AF, Otto MW, Harlow BL. Risk for new onset of depression during the menopausal transition: the Harvard Study of Moods and Cycles. Arch Gen Psychiatry. 2006;63(4):385–390.
- Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry. 2018;75(2):149–157. doi:10.1001/jamapsychiatry.2017.3998
- Thurston RC, El Khoudary SR, Tepper PG, et al. Trajectories of vasomotor symptoms and carotid intima media thickness in the Study of Women's Health Across the Nation. Stroke. 2016;47(1):12–17. doi:10.1161/STROKEAHA.115.010600
- "The 2022 Hormone Therapy Position Statement of The North American Menopause Society" Advisory Panel. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028
- Manson JE, Crandall CJ, Rossouw JE, et al. The Women's Health Initiative randomized trials and clinical practice: a review. JAMA. 2024;331(20):1748–1760. doi:10.1001/jama.2024.6542